Several ongoing trials (NCT05770037, NCT04925609, and NCT05384626) continue to explore the broad applicability of ALK inhibitors across different cancer types, focusing on treatment resistance, brain metastases, and CNS-related side effects [62]. Here, ALK is linked to cancer.